COVID-19 Infection-Related Coagulopathy and Acute Limb Ischemia in a Patient With Pre-existing Diabetes

Abstract

The pandemic of coronavirus 19 infection has presented the clinicians with a challenge never experienced on this scale before. Although coagulopathy has been well described in association with COVID-19 infection, some recommendations have emerged so far for the potential role of empiric anticoagulation in specific situations. We describe a case of a middle-aged male with extensive acute lower limb ischemia and severe pneumonia related to COVID-19 infection. This case highlights the role of prophylactic anticoagulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection regardless of co-morbidities and D-dimer levels.

Revascularization prevents amputation among patients with diabetic foot during the COVID-19 era

“…An elective revascularization procedure was performed with a margin of up to 14 days from their first scheduled visit to our service (WIFI stage I), urgent revascularization with a margin of up to 7 days (WIFI stage II and III), and emergency procedure with a margin of up to 48 h (WIFI IV). 11 These concepts did not change before and during the COVID-19 pandemic, even during disease surges.…”

“…10 Exclusion criteria were acute limb ischemia, defined as an abrupt decrease in limb arterial perfusion with consequent threatened limb viability and patients with previous or active SARS-CoV-2 infection during the index hospitalization. 11 During 2020, all hospitalized patients underwent respiratory triage including chest x-ray, and those with respiratory symptoms underwent testing of nasopharyngeal swab specimens by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR); patients who tested positive for SARS-CoV-2 infection were excluded.…”